Denis McCann

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

Sheng-Bin Peng, James R. Henry, Michael D. Kaufman et al. · Cancer Cell · 2015 · 309 citations · Full text

Medicine, Cancer Biology, Oncology +16

Therapeutic Inhibition of MAP Kinase Interacting Kinase Blocks Eukaryotic Initiation Factor 4E Phosphorylation and Suppresses Outgrowth of Experimental Lung Metastases

Bruce W. Konicek, Jennifer R. Stephens, Ann M. McNulty et al. · Cancer Research · 2011 · 188 citations · Full text

Medicine, Oncology, Pharmacology +17

A Novel, Selective Inhibitor of Fibroblast Growth Factor Receptors That Shows a Potent Broad Spectrum of Antitumor Activity in Several Tumor Xenograft Models

Genshi Zhao, Weiying Li, Daohong Chen et al. · Molecular Cancer Therapeutics · 2011 · 188 citations

Medicine, Oncology, Pharmacology +13

Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity

Robert M. Campbell, Bryan D. Anderson, Nathan A. Brooks et al. · Molecular Cancer Therapeutics · 2013 · 116 citations

Medicine, Oncology, Pharmacology +13

ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine

Shripad V. Bhagwat, William T. McMillen, Shufen Cai et al. · Molecular Cancer Therapeutics · 2019 · 108 citations · Full text

Medicine, Oncology, Pharmacology +17